相似文献
1
To filter blood or universal leukoreduction: what is the answer?
Crit Care. 2004;8 Suppl 2(Suppl 2):S27-30. doi: 10.1186/cc2453. Epub 2004 Jun 14.
2
AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections.
Transfusion. 2016 Jun;56(6 Pt 2):1581-7. doi: 10.1111/trf.13503. Epub 2016 Mar 10.
3
Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.
Transfusion. 2016 Jun;56(6 Pt 2):1569-80. doi: 10.1111/trf.13478. Epub 2016 Jan 29.
4
Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs.
Transfusion. 2004 Jan;44(1):25-9. doi: 10.1046/j.0041-1132.2004.00609.x.
5
Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
Transfusion. 2010 Apr;50(4):776-86. doi: 10.1111/j.1537-2995.2009.02486.x. Epub 2009 Nov 13.
6
Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching.
Ann Hematol. 2024 Apr;103(4):1389-1396. doi: 10.1007/s00277-024-05652-9. Epub 2024 Feb 23.
7
Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line.
J Clin Virol. 1998 Aug 20;11(2):109-16. doi: 10.1016/s1386-6532(98)00047-6.
8
Why implement universal leukoreduction?
Hematol Oncol Stem Cell Ther. 2008 Apr-Jun;1(2):106-23. doi: 10.1016/s1658-3876(08)50042-2.
9
[Clinical applications of leukocyte filters].
Rev Assoc Med Bras (1992). 1997 Jul-Sep;43(3):205-8. doi: 10.1590/s0104-42301997000300007.
10
Universal leukocyte reduction: Is it appropriate medical practice or not?
J Infus Nurs. 2005 Jul-Aug;28(4):273-81. doi: 10.1097/00129804-200507000-00010.
引用本文的文献
1
An evaluation of diethylhexyl phthalate free top & bottom in-line blood collection set with a new soft housing filter.
Transfus Med. 2025 Feb;35(1):82-90. doi: 10.1111/tme.13091. Epub 2024 Sep 7.
2
Informing the State of Process Modeling and Automation of Blood Banking and Transfusion Services Through a Systematic Mapping Study.
J Multidiscip Healthc. 2024 Feb 1;17:473-489. doi: 10.2147/JMDH.S443674. eCollection 2024.
3
Transfusion support in hematopoietic stem cell transplantation.
Blood Res. 2023 Apr 30;58(S1):S1-S7. doi: 10.5045/br.2023.2023004. Epub 2023 Feb 27.
4
Transfusion-associated adverse events and implementation of blood safety measures - findings from the 2017 National Blood Collection and Utilization Survey.
Transfusion. 2020 Mar;60 Suppl 2(Suppl 2):S10-S16. doi: 10.1111/trf.15654.
5
A comparison of different methods of red blood cell leukoreduction and additive solutions on the accumulation of neutrophil-priming activity during storage.
Transfusion. 2018 Aug;58(8):2003-2012. doi: 10.1111/trf.14788. Epub 2018 Sep 1.
6
Mechanisms of red blood cell transfusion-related immunomodulation.
Transfusion. 2018 Mar;58(3):804-815. doi: 10.1111/trf.14488. Epub 2018 Jan 30.
7
Factors Affecting Tissue Oxygenation in Erythrocyte Transfusions.
Turk J Anaesthesiol Reanim. 2014 Jun;42(3):111-6. doi: 10.5152/TJAR.2014.112014. Epub 2014 Jun 1.
8
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion.
Cochrane Database Syst Rev. 2015 Dec 3;2015(12):CD009745. doi: 10.1002/14651858.CD009745.pub2.
9
Effects of Prestorage Leukoreduction on the Rate of Febrile Nonhemolytic Transfusion Reactions to Red Blood Cells in a Tertiary Care Hospital.
Ann Med Health Sci Res. 2015 May-Jun;5(3):185-8. doi: 10.4103/2141-9248.157498.
10
Resuscitation with washed aged packed red blood cell units decreases the proinflammatory response in mice after hemorrhage.
J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S128-33. doi: 10.1097/TA.0b013e3182606301.
本文引用的文献
1
WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials.
Transfusion. 2003 Jul;43(7):963-73. doi: 10.1046/j.1537-2995.2003.00426.x.
2
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.
JAMA. 2003 Apr 16;289(15):1941-9. doi: 10.1001/jama.289.15.1941.
3
A prospective, randomized clinical trial of universal WBC reduction.
Transfusion. 2002 Sep;42(9):1114-22. doi: 10.1046/j.1537-2995.2002.00182.x.
4
Leukoreduction of blood components.
Curr Opin Hematol. 2002 Nov;9(6):521-6. doi: 10.1097/00062752-200211000-00010.
5
Universal leukoreduction of cellular blood components in 2001? No.
Am J Clin Pathol. 2001 May;115(5):674-7. doi: 10.1309/H9QA-LMGL-NLJY-F0P2.
6
Universal leukoreduction of cellular blood components in 2001? Yes.
Am J Clin Pathol. 2001 May;115(5):666-73. doi: 10.1309/XG61-NB7Q-JM59-PK98.
7
Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.
JAMA. 2001 Mar 28;285(12):1592-601. doi: 10.1001/jama.285.12.1592.
8
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
J Clin Oncol. 2001 Mar 1;19(5):1519-38. doi: 10.1200/JCO.2001.19.5.1519.
9
Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells.
Transfusion. 1999 Oct;39(10):1089-96. doi: 10.1046/j.1537-2995.1999.39101089.x.
10
Leukoreduction of the blood supply in Rhode Island.
Med Health R I. 1998 Dec;81(12):386-91.
Zotero 插件